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Background: Acute heart failure (AHF) is a common presentation in the Emergency Depart-
ment (ED), and most patients are admitted to the hospital. Identification of patients with AHF 
who have a low risk of adverse events and are suitable for discharge from the ED is difficult, 
and an objective tool would be useful.
Methods: The highly sensitive Troponin T Rules Out Acute Cardiac Insufficiency Trial (TACIT) 
will enroll ED patients being treated for AHF. Patients will undergo standard ED evaluation and 
treatment. High-sensitivity troponin T (hsTnT) will be drawn at the time of enrollment and 3 
hours after the initial draw. The initial hsTnT draw will be no more than 3 hours after initiation 
of therapy for AHF (vasodilator, loop diuretic, noninvasive ventilation). Treating clinicians will 
be blinded to hsTnT results. We will assess whether hsTnT, as a single measurement or in series, 
can accurately predict patients at low risk of short-term adverse events.
Conclusion: TACIT will explore the value of hsTnT measurements in isolation, or in combina-
tion with other markers of disease severity, for the identification of ED patients with AHF who 
are at low risk of short-term adverse events.
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Introduction
Acute heart failure (AHF) is a major public health problem, accounting for over 1 
million hospitalizations annually in the US.1 The vast majority of these admissions 
are through the Emergency Department (ED),1–3 where 85% of patients with AHF are 
hospitalized.3 These patients carry ~4% risk for mortality during their hospitalization, 
and the risk of death approaches 12% within 30 days after discharge.4 Additionally, 
nearly 35% are dead or rehospitalized within 90 days of discharge.5 Consequently, ED 
physicians are hesitant to discharge patients with AHF and generally admit them to the 
hospital. This results in enormous morbidity as well as financial costs.1,5
Identifying a subgroup of ED patients with AHF where hospitalization can be 
avoided either by direct discharge or after a brief stay in an observation unit is a critical 
evidence gap.6–8 The Agency for Health care Research and Policy Guidelines has sug-
gested that up to 50% of AHF patients could be discharged from the ED or observed 
for a brief period.9 Unfortunately, defining those patients appropriate for discharge 
has proven difficult. Certain “high-risk” features, such as low blood pressure, high 
natriuretic peptide (NP), or cardiac-specific troponin concentrations,10–12 worsening 
renal function, and hyponatremia, are all associated with poor outcomes.13 However, the 
absence of these high-risk features does not guarantee a good outcome.  Accordingly, 
there is no universally accepted AHF patient group considered “safe” to discharge 
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from the ED. Certain risk stratification tools show promise, 
though further research is needed. The 13-item STRATIFY 
(Improving Heart Failure Risk Stratification in the ED) pre-
diction tool14 was prospectively derived from a cohort of over 
1,000 ED patients with AHF. In the STRATIFY derivation 
study, 7% of enrolled patients experienced a cardiovascular 
(CV) event within 5 days and 12% experienced an event 
within 30 days. The model was able to risk-stratify patients 
for serious events with a c-statistic of 0.68 (95% confidence 
interval: 0.63–0.74). The negative predictive values for iden-
tifying true low-risk patients was 100% at a 3% threshold for 
events, 96% at a 5% threshold, and 93% at a 10% threshold. 
The authors concluded that 13% of their patients could have 
been discharged with a very low risk of CV events. Other 
risk stratification tools have been derived as well, but none 
has gained widespread adoption for disposition decision 
making.15,16 Identification of patients safe for ED discharge 
remains an unmet need.
While contemporary troponin assays have both diagnostic 
and prognostic value in the management of patients with AHF, 
next-generation high-sensitivity cardiac troponins (hsTn) can 
detect more minor degrees of myocardial injury.10–12 The abil-
ity to quantify lower amounts of released troponin, and thus 
identify patients without such elevations, may discriminate 
patients at very low risk for adverse CV events and death.17 A 
recent post hoc analysis from a therapeutic trial demonstrated 
the absence of CV deaths through 180 days in patients with 
low high-sensitivity cardiac troponin T (hsTnT) levels.18 This 
hypothesis-generating finding requires prospective external 
testing in a broader population of ED patients with AHF. 
Thus, we designed the high-sensitivity cardiac Troponin 
T Rules Out Acute Cardiac Insufficiency Trial (TACIT), a 
multicenter, prospective, observational pilot study. TACIT 
will test whether serial negative hsTnT measurements can 
identify low-risk AHF patients in the ED who are safe for 
discharge or brief observation. TACIT will provide pilot data 
sufficient to inform the design of a definitive trial to test this 
hypothesis. Our secondary objective will be to externally 
validate the STRATIFY risk score.
Design
TACIT is a pragmatic, multicenter, prospective, observa-
tional, cohort pilot trial to test the value of serial hsTnT 
measurements in order to identify ED patients with AHF 
who are at very low risk of adverse outcomes. At least 500 
patients will be enrolled across five hospitals at four aca-
demic centers. All sites will have approval from their local 
ethics committee or institutional review board. All patients 
enrolled in TACIT will provide written informed consent. 
Highly qualified research teams will lead the study at their 
respective sites after being trained by the study primary 
investigator and team.
Study population
Formal inclusion and exclusion criteria are listed in Table 1. 
Enrolled patients will be aged ≥21 years and will be diag-
nosed with AHF by the treating emergency physician. Patients 
will have received therapy for AHF (diuretics, vasodilators, 
noninvasive ventilation, etc), and will have a blood pressure 
>100 mmHg. In keeping with the pragmatic, “real-world” 
design, the diagnosis of AHF will be made clinically by a 
treating physician with enough confidence that treatment 
for AHF in being initiated. We chose pragmatic criteria to 
facilitate early enrollment of patients who were diagnosed 
with and treated for AHF in the ED. While the ED diagnosis 
may not always agree with the hospital discharge diagnosis,6 
this is the population of interest and reflects “real-world” 
clinical practice. Enrollment must occur within 3 hours of 
first ED therapy for AHF. We chose 3 hours as a reasonable 
timeframe to begin consideration of ED discharge.
The study design targets low-risk patients, as high-risk 
patients are readily identified by established prognostic 
markers. Subsequently, we chose to exclude patients who 
would be considered too complex to discharge, even if both 
hsTnT were normal and other criteria suggested low risk. As 
such, patients with life expectancy ≤6 months, active cancer, 
history of heart transplant or ventricular assist device, renal 
disease requiring dialysis, hypotension (systolic blood pres-
sure <100 mmHg), use of inotropes or vasopressors, fever 
>101.5°F, acute coronary syndrome (ACS) as the cause for 
AHF (based on the presence of typical signs or symptoms, or 
new electrocardiogram changes) or documented ACS within 
the previous 30 days, atrial fibrillation with heart rate >130, 
known substance abuse likely to make follow-up difficult, or 
involvement in any interventional trial are excluded. Inclu-
sion and exclusion criteria are detailed in Table 1.
This study has been registered at ClinicalTrials.gov, 
identifier NCT02592135.
Study protocol
TACIT will enroll patients as a convenience sample, based 
on study personnel availability at each site. At minimum, this 
will be Monday through Friday from 8 am to 5 pm. For some 
sites, 24/7 enrollment is possible. Patients will be prescreened 
according to chief complaint using an Institutional Review 
Board-approved screening protocol of ED electronic health 
records. Patients will be aged ≥21 years with complaints 
possibly attributable to AHF, such as dyspnea, shortness of 
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breath, chest pain, leg swelling or edema, or weight gain, will 
be screened for enrollment. Those who meet the inclusion and 
exclusion criteria will be approached for written informed 
consent by trained study personnel. A screening log will be 
kept of all patients screened for possible enrollment.
As part of ED standard practice, patients will have blood 
draws including electrolytes, troponin, NPs, and hematology 
studies. Standard practice also includes obtaining an electro-
cardiogram and chest X-ray. Test results will be recorded by 
the study personnel once the patient is enrolled. Additionally, 
detailed demographics, past medical history, and medication 
lists will be obtained. Objective physical exam findings such 
as vital signs, weight, temperature, and height will also be 
recorded. ED treatments, disposition, and diagnoses will be 
recorded. These data will be entered into a secure, protected, 
online case report form using REDCap.19
In addition to standard care, once enrolled, patients will 
undergo baseline (0-hour) and 3-hour (±1 hour) blood draws 
for hsTnT, as well as N-terminal prohormone of brain natri-
uretic peptide. Once drawn, these samples will be frozen 
and stored for central processing. Clinicians will be blinded 
to the cardiac troponin T results. The 0-hour hsTnT blood 
draw must occur within 3 hours of the first AHF treatment 
(ie, loop diuretic or vasodilator or noninvasive ventilation) 
given in the ED.
Follow-up will occur 90 days after discharge, whether 
 discharge occurred from the ED or after an inpatient 
 admission. Discharge from the hospital will be counted as 
day 5 in the hospital or the actual day of discharge, which-
ever comes first. As the median length of stay is 4 days in 
the US, and our focus is on low-risk patients, we chose day 
5 to minimize the confounding effect of very long length of 
stay patients. However, we will record overall length of stay 
to allow for additional analyses. Medical records will be 
reviewed for all patients. Vital status phone calls will occur 
at 30 and 90 days after discharge. Additionally, at least three 
attempts at phone contact will be attempted, and if unsuccess-
ful, an additional two attempts to an alternate contact will be 
undertaken. Dates of all events will be recorded.
Follow-up was initially planned for 30 days only. How-
ever, after 20% of the planned enrollment, a review of 
demographics and outcomes was undertaken. This review 
was blinded to all hsTnT results. It was noted that the event 
rate was lower than expected, and the decision was made to 
follow patients to 90 days instead of only 30. For patients 
enrolled prior to this protocol change, 30-day phone follow-
up was completed as per the original protocol. Additionally, 
there will be a 90-day medical record review to assess for 
further events.
Endpoints
Table 2 describes the clinical endpoints that will be evalu-
ated in TACIT. The primary endpoint will be a composite 
of 90-day all-cause mortality and rehospitalization, includ-
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
1. Age ≥21 years  1. Life expectancy ≤6 months
2. Patient diagnosed with AHF by the treating physician  2. Shock of any kind or use or planned use of inotropes (dobutamine, 
dopamine, milrinone) or vasopressors. Any form of vasodilator is allowed
3. Patient has received IV loop diuretic or vasodilator therapy 
(by any route) or NIV for AHF
 3. Fever >101.5°F
4. Provide informed written consent  4. Presumed ACS as the primary reason for presentation or ACS within 30 
days. Patients with troponin release outside of ACS (Type 2 MI) may be 
included
5. SBP >100 mmHg (SBP <100 at any time is an exclusion)  5. AF with RVR >130 bpm at any time requiring medical intervention
6. Enrolled within 3 hours of first AHF therapy  6. History of transplant of any kind or VAD patient
 7. ESRD requiring dialysis
 8. Involved in any investigational trial (observational study where no 
intervention is allowed)
 9. Currently under treatment for cancer of any kind
 10. Known history of active alcoholism or drug abuse that may lead to 
noncompliance
 11. Participating in any other interventional therapeutic or device trial
 12. Any patient whom the investigator deems would be difficult to obtain 
follow-up
Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; AHF, acute heart failure; ESRD, end-stage renal disease; IV, intravenous; MI, myocardial infarction; NIV, 
noninvasive ventilation; RVR, rapid ventricular response; SBP, systolic blood pressure; VAD, ventricular assist device.
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ing ED revisits. Secondary and exploratory endpoints will 
include days alive and out of the hospital, CV-specific 
rehospitalization and ED revisits, all-cause mortality, 
cardiopulmonary resuscitation, mechanical cardiac sup-
port, mechanical ventilation, emergent dialysis, ACS, and 
percutaneous coronary intervention/coronary artery bypass 
grafting. Each site will perform their own adjudication of 
events, blinded to hsTn results. For the endpoint of myo-
cardial infarction, the diagnosis will be based on standard 
diagnostic algorithms requiring an elevation in (nonhighly 
sensitive) troponin above the 99th percentile with a typical 
rise and fall of the biomarker.
Evaluation of the prognostic value 
of hsTnT
The prognostic value of negative serial hsTnT values for the 
composite endpoint of 90-day mortality and rehospitaliza-
tion will be evaluated using a variety of methods, given the 
observational, descriptive study design. We will test the 99th 
percentile and manufacturers-suggested cutoff (including 
gender-based cutpoints) as potential thresholds for abnor-
mal. Additionally, we will perform an Area Under the Curve 
Receiver Operating Characteristic analysis to determine 
optimal thresholds for hsTn in relation to outcomes. First, 
we will examine the sensitivity, specificity, and the c-statistic 
for hsTnT. Second, we will examine the event rate within 
each quartile of the hsTnT distribution and test any trend 
using a Mantel–Haenszel test. Third, we will use logistic 
regression to examine the added prognostic value of hsTnT 
in addition to known prognostic factors such as age, gender, 
serum sodium, blood pressure, NP concentrations, and renal 
function. We will compute net reclassification indices and 
integrated discrimination improvement for this purpose.
Sample size considerations
Based on previously published literature, we estimated ~25% 
of patients will meet the primary endpoint of death or rehos-
pitalization by 30 days. This would require ~400 patients in 
order to achieve 100 events. With 100 events, we will be able 
to control the error in the sensitivity estimate within ±10% 
and the error in the specificity estimate within ±6%. Given our 
enrollment criteria targeting low-risk patients, we estimated 
a sample size of 500 patients. Gender-specific percentiles 
of hsTn will be tested, and other subgroup analyses will be 
explored, given the design as a pilot study. These include, but 
are not limited to the subgroups such as age, gender, ejection 
fraction, systolic blood pressure, organ injury biomarkers, 
and NP levels. A blinded interim analysis will occur after 
250 patients are enrolled.
Discussion
Patients presenting to the ED with AHF are admitted at an 
alarmingly high rate.3 Ironically, this conservative approach 
leads to admissions for patients in whom there is no proven 
inpatient treatment to improve outcomes or reduce mortal-
ity. Diuretics, vasodilators, and inotropes are used to treat 
patients with AHF, yet none have been proven effective in 
reducing mortality among these patients. Despite the high 
overall morbidity of this population, a subset of AHF patients 
likely carry a good short-term prognosis.14–16 Whether 
admission in these low-risk patients offers any alteration 
in prognosis is unclear. Many patients might be safely 
discharged with a low risk of short-term adverse events,9 
sparing the significant costs and morbidity associated with 
hospitalizations. A decision tool to identify low-risk patients 
and increase physician confidence for safe discharge would 
be of great value. TACIT aims to evaluate the usefulness of 
hsTnT measurements, in isolation or in conjunction with 
other clinical variables, for identifying AHF patients in the 
ED who are at lower risk for adverse events. If hsTnT can, 
in isolation, accurately identify patients who are at low risk, 
it may obviate the need for more complex decision scores. 
A single simple marker to identify low-risk patients with 
AHF would fulfill an unmet need. While patients enrolled 
in TACIT will not be sent home based on hsTnT results, 
the results will inform the design of a larger multicenter, 
definitive trial.
Table 2 TACIT endpoints
Primary outcome
Composite of death or rehospitalization, including repeat ED visit
Secondary outcome
STRATIFY risk score
Exploratory outcomes
The STRATIFY risk score comprises the following:
1. All-cause mortality
2. Days alive and out of the hospital
3. CV-specific rehospitalization and ED revisits
4. Cardiopulmonary resuscitation
5. Mechanical cardiac support
6. Intubation or mechanical ventilation
7. Emergent dialysis
8. Percutaneous coronary intervention or coronary artery bypass 
grafting
9. Acute coronary syndrome
Abbreviations: CV, cardiovascular; ED, emergency department; STRATIFY, 
Improving Heart Failure Risk Stratification in the ED; TACIT, Troponin T Rules Out 
Acute Cardiac Insufficiency Trial.
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Other ED-based AHF risk 
stratification scores
Previous studies have attempted to accurately risk-stratify 
patients with AHF in the hopes of identifying a subset of 
patients safe for discharge either immediately or after a brief 
ED observation. Lee et al risk-stratified AHF patients in 
terms of 7-day mortality using large administrative datasets.16 
The authors randomly selected over 12,000 charts from 125 
hospitals in Ontario, Canada for detailed abstraction. They 
included both admitted and discharged patients with AHF 
in the ED. Their final model included ten variables. They 
identified 25% of patients who had a <0.5% risk of death at 
7 days. However, this dataset did not include adverse events 
other than mortality, or outcomes beyond 7 days, which may 
not be long enough to give clinicians confidence to discharge 
patients. In addition, Canadian hospitals tend to have a higher 
ED discharge rate than US hospitals, potentially confound-
ing comparisons.
In a validation of the AHF Index, Hsieh et al identified 
19% of 8,384 AHF patients admitted to Pennsylvania hos-
pitals as low risk. Among these low-risk patients, 2.4% had 
a serious in-hospital complication or died before hospital 
discharge, and 30-day mortality was 2.9%.15 Results such as 
these have not given clinicians the confidence to adopt any 
current tools as disposition aids, and no stratification system 
has yet attained widespread adoption.
Among risk stratification studies, the largest prospective 
trial performed in an ED setting was the STRATIFY study.14 
TACIT will attempt to validate these findings in a new popula-
tion of prospectively enrolled ED patients with AHF.
A common theme among all of these risk stratification 
scores14–16: elevated troponin is highly predictive of both death 
and other serious CV events. Troponin is arguably the most 
predictive single laboratory test available for prognosis in 
patients with cardiac disease, and even in many patients with 
noncardiac pathology. Given the established prognostic value 
of troponin across a wide variety of conditions, including 
heart failure, we hypothesize that hsTn measurements will 
add significant value to current risk stratification.
Limitations
There are several important limitations to the TACIT pilot 
study. Foremost, it is observational in nature, and thus, we 
cannot use the findings to establish a causal relationship 
between use of hsTnT and patient outcomes. Further, we 
rely on physician assessment for the diagnosis of AHF. While 
we expect that there may be cases misclassified as AHF, our 
design allows a pragmatic approach to assessment of patients 
seen in the ED and thought to be suffering from AHF. This 
design will be important for real-world application of hsTn 
as a marker of low risk. Additionally, participating centers 
will be enrolling patients as a convenience sample. There may 
be some differences between patients with AHF presenting 
during “off hours” as opposed to those that we will capture 
during the day on weekdays. Because TACIT is being car-
ried out at four academic referral centers, results in general 
may not be applicable to settings that differ in demographic, 
socioeconomic, or other baseline characteristics. Our study 
is also likely to be underpowered for outcomes other than 
our composite endpoint of mortality and rehospitalization. 
Rehospitalization itself is subject to factors that make it less 
objective than mortality, such as the risk tolerance of physi-
cians and the preferences of each patient concerning their 
own dispositions. Despite this, rehospitalization is a common 
endpoint in AHF literature and carries importance to patients, 
clinicians, and payors.
Conclusion
The TACIT study will test the hypothesis that hsTnT mea-
surements, either at presentation or serially, will provide 
clinically important prognostic information in patients with 
AHF who are not otherwise at high risk for adverse outcomes. 
Specifically, we hope to derive a decision instrument utilizing 
hsTnT in conjunction with other markers of disease severity 
that identifies patients with AHF who are at very low risk of 
90-day adverse events.
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